Earnings ·
Calidi Biotherapeutics reported a net loss of $4.2 million ($2.94 per share) for the second quarter ended June 30…
CLDWWCalidi Biotherapeutics, Inc.
Calidi Biotherapeutics reported a net loss of $4.2 million ($2.94 per share) for the second quarter ended June 30, 2026, compared to a $5.7 million loss in the prior year period. The company received positive pre-IND feedback from the U.S. FDA for its lead candidate CLD-401, aligning on development strategy toward first-in-human dosing in Q1 2027. Additionally, Calidi presented new data on its RedTail platform at ASCO and added Corsee Sanders to its Board of Directors. General and administrative expenses decreased by $1.5 million (48%) year-over-year to $1.6 million. The company held $4.1 million in cash as of June 30, 2026. Calidi Biotherapeutics is a biotechnology company pioneering the development of targeted genetic medicines using its proprietary RedTail platform.